Clinical trial · no report yet · Phase 3
NCT03391869
Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
- NCT03391869 ↗
- Active, not recruiting
- M.D. Anderson Cancer Center
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 18 | |
| YouTube | 5 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Lung Adenocarcinoma; Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8
- Interventions
- Ipilimumab; Local Consolidation Therapy; Nivolumab; Quality-of-Life Assessment; Radiation Therapy; Therapeutic Conventional Surgery
- Arms
- Arm A (ipilimumab, nivolumab) · Experimental
- Arm B (ipilimumab, nivolumab, LCT) · Experimental
- Enrollment
- 339
- Primary outcomes
- Overall survival (OS) in overall population
- OS in oligometastatic subgroup
- Sponsor
- M.D. Anderson Cancer Center
- Start
- Dec 29, 2017
- Primary completion
- Mar 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT03391869 · updated Sep 18, 2026
Publications
linked from the registry- Altan M, Li R, Li Z, Chen R, Sheshadri A, Tran HT, Little L, Baguley J, Sinson J, Vokes N, Gandhi S, Antonoff MB, Swisher SG, Lizee G, Reuben A, Heymach JV, Zhang J. High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC. J Immunother Cancer. 2024 Dec 25;12(12):e008950. doi: 10.1136/jitc-2024-008950. PubMed 39721752
- Altan M, Li QZ, Wang Q, Vokes NI, Sheshadri A, Gao J, Zhu C, Tran HT, Gandhi S, Antonoff MB, Swisher S, Wang J, Byers LA, Abdel-Wahab N, Franco-Vega MC, Wang Y, Lee JJ, Zhang J, Heymach JV. Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events. Front Immunol. 2023 Dec 12;14:1322818. doi: 10.3389/fimmu.2023.1322818. eCollection 2023. PubMed 38152395